ClinicalTrials.gg
CompletedNCT05616013Updated Jul 8, 2026Results posted

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

A Phase 2 interventional study of Bimagrumab and Semaglutide in Obesity, Obese and Overweight or Obesity, sponsored by Eli Lilly and Company. Completed at 26 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
507
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 118 studies in Obesity by Eli Lilly and Company — 31 open to participants now, 55 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.

Enrollment
36th of 117
507 · median 267
Started
2022
with 9 others
Phase 2
22 of 118
5 open now
Registered
24th of 118
by date

Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 36th largest by enrollment of the 117 interventional ones that give a count, is one of 10 that started in 2022, is one of 22 in phase 2, and was the 24th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

31 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Obesity by Eli Lilly and Company, or all of them as a file.
02

Study summary

A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women

Read the detailed description

This study investigates if bimagrumab in addition to semaglutide is able to preserve/increase muscle mass in the presence of weight and/or fat mass loss.

03

Conditions studied

  • Obesity
  • Obese
  • Overweight or Obesity

Keywords

  • bimagrumab
  • semaglutide
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • A written must be obtained before any study-related assessments are performed.
  • Men and women between 18 and 80 years, inclusive; women of (defined as those who are not or post-surgical sterilization) must meet both of the following criteria:

    • Two negative pregnancy tests (at screening and at randomization, prior to dosing)
    • Use of intrauterine device, from at least 3 months before the baseline visit through at least 4 months after the last dose of bimagrumab/placebo i.v., and an additional (barrier) method from screening through at least 4 months after the last dose of bimagrumab/placebo i.v.
  • (BMI) ≥ 30 or BMI ≥ 27 with one or more obesity-associated comorbidities (e.g., hypertension, insulin resistance, sleep apnea, or dyslipidemia)
  • Stable body weight (± 5 kg) within 90 days of screening, and body weight \<150 kg
  • Have a history of at least one self-reported unsuccessful behavioral effort to lose body weight
  • Able to communicate well with the Investigator, comply with the study requirements and adhere to the diet and activity programs for the study duration

Key Exclusion Criteria:

  • History of, or known to, monoclonal antibody drugs or a to semaglutide (Ozempic® or Wegovy®)
  • Use of other drugs at the time of enrollment or within 30 days or 5 half-lives of enrollment, whichever is longer, or longer if required by local regulations
  • Treatment with any medication for the indication of obesity within the past 30 days before screening
  • Diagnosis of diabetes requiring current use of any antidiabetic drug or ≥ 6.5% Note: Metabolic syndrome is not an exclusion, even if managed with an anti-diabetic drug such as metformin or an SGLT2 inhibitor. A diagnosis of prediabetes or impaired glucose tolerance managed exclusively with non-pharmacologic approaches (e.g., diet and exercise) is not an exclusion.
  • Any chronic infections likely to interfere with study conduct or interpretation such as (HBV), (HCV), or (HIV). History of hepatitis A or hepatitis C successfully treated is not exclusionary. Active COVID-19 infection.
  • Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing, or longer if required by local regulation, or plasma donation (> 250 mL) within 14 days prior to the first dose
  • Any disorder, unwillingness, or inability not covered by any of the other exclusion criteria, which in the Investigator's opinion, might jeopardize the participant's safety or compliance with the protocol
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
507 participants (actual)

Study arms

  • Placebo comparator
    Placebo/30 mg/kg Bimagrumab

    Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64.

    Other: Placebo

  • Experimental
    10/30 mg/kg Bimagrumab

    Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64.

    Biological: Bimagrumab

  • Experimental
    30 mg/kg Bimagrumab

    Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64.

    Biological: Bimagrumab

  • Experimental
    Placebo + 1.0 mg Semaglutide

    Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg

    Drug: Semaglutide · Other: Placebo

  • Experimental
    Placebo + 2.4 mg Semaglutide

    Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg

    Drug: Semaglutide · Other: Placebo

  • Experimental
    10 mg/kg Bimagrumab + 1.0 mg Semaglutide

    Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg

    Biological: Bimagrumab · Drug: Semaglutide

  • Experimental
    10 mg/kg Bimagrumab + 2.4 mg Semaglutide

    Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg

    Biological: Bimagrumab · Drug: Semaglutide

  • Experimental
    30 mg/kg Bimagrumab + 1.0 mg Semaglutide

    Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg

    Biological: Bimagrumab · Drug: Semaglutide

  • Experimental
    30 mg/kg Bimagrumab + 2.4 mg Semaglutide

    Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg

    Biological: Bimagrumab · Drug: Semaglutide

Interventions

  • BiologicalBimagrumab

    Human monoclonal antibody to the activin receptor type II

  • Glucagon-like peptide-1 (GLP-1) receptor agonist

    Also known as: Wegovy, Ozempic

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Body Weight at Week 48

    Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Change From Baseline in Waist Circumference at Week 48

    Waist circumference was measured in standing position with a non-stretchable measuring tape to the nearest 0.1 centimeter (cm). Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 48

  2. Change From Baseline in Waist Circumference at Week 72

    Waist circumference was measured in standing position with a non-stretchable measuring tape to the nearest 0.1 cm. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 72

  3. Change From Baseline in Total Body Fat Mass in Kilograms (kg) at Week 48

    Change from baseline in total body fat mass in kg was assessed by Dual energy X-ray absorptiometry (DXA). Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 48

  4. Change From Baseline in Total Body Fat Mass in kg at Week 72

    Change from baseline in total body fat mass in kg was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 72

  5. Percent Change From Baseline for Fat Mass by DXA at Week 48

    Percent change from baseline for fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 48

  6. Percent Change From Baseline for Fat Mass by DXA at Week 72

    Percent change from baseline for fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 72

  7. Change From Baseline in Visceral Adipose Tissue (VAT), Subcutaneous Adipose Tissue (SAT) and Trunk Fat Mass by DXA at Week 48

    Change from baseline in VAT, SAT and trunk fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 48

  8. Change From Baseline in VAT, SAT and Trunk Fat Mass by DXA at Week 72

    Change from baseline in VAT, SAT and trunk fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 72

  9. Percentage of Participants With Reduction in Waist Circumference Greater Than or Equal to (≥) 5 cm at Week 48

    Waist circumference was measured in a standing position with a non-stretchable measuring tape to the nearest 0.1 cm. Only participants with non-missing baseline value were included in analysis.

    Time frame: Week 48

  10. Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48

    Body weight was measured in kgs to the nearest 0.1 kg. Only participants with non-missing baseline value were included in analysis.

    Time frame: Week 48

  11. Percentage of Participants With Reduction in Fat Mass ≥ 5% ≥ 10% ≥ 15% by DXA at Week 48

    Only participants with non-missing baseline value were included in analysis.

    Time frame: Week 48

  12. Percentage of Participants Achieving Fat Mass ≥ 10% Reduction With <5% Decrease in Lean Mass by DXA at Week 48

    Only participants with non-missing baseline value were included in analysis.

    Time frame: Week 48

  13. Percentage of Participants Achieving >5 kg Weight Loss and Fat Loss Index (FLI) of >70%, >80%, and >90% by DXA at Week 48

    Fat Lost Index = % change in fat mass/% change in lean mass + % change in fat mass. Only participants with non-missing baseline value were included in analysis.

    Time frame: Week 48

  14. Change From Baseline in Body Fat Mass by Bioelectrical Impedance Analysis (BIA) at Week 48

    Change from baseline in body fat mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

    Time frame: Baseline, Week 48

  15. Change From Baseline in Body Fat Mass by BIA at Week 72

    Change from baseline in body fat mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

    Time frame: Baseline, Week 72

  16. Percent Change From Baseline in Body Fat by BIA at Week 48

    Percent change from baseline in Body fat was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

    Time frame: Baseline, Week 48

  17. Percent Change From Baseline in Body Fat by BIA at Week 72

    Percent change from baseline in Body fat was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

    Time frame: Baseline, Week 72

  18. Change From Baseline in Lean Mass by DXA at Week 48

    Change from baseline in lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 48

  19. Change From Baseline in Lean Mass by DXA at Week 72

    Change from baseline in lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 72

  20. Percent Change From Baseline in Lean Body Mass by DXA at Week 48

    Percent change from baseline in lean body mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 48

  21. Percent Change From Baseline in Lean Body Mass by DXA at Week 72

    Percent change from baseline in lean body mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 72

  22. Percent Change From Baseline in Appendicular Lean Mass by DXA at Week 48

    Percent change from baseline in appendicular lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 48

  23. Percent Change From Baseline in Appendicular Lean Mass by DXA at Week 72

    Percent change from baseline in appendicular lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, Week 72

  24. Change From Baseline in Lean Mass (kg) by BIA at Week 48

    Change from baseline in lean mass (kg) was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

    Time frame: Baseline, Week 48

  25. Change From Baseline in Lean Mass (kg) by BIA at Week 72

    Change from baseline in lean mass (kg) was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

    Time frame: Baseline, Week 72

  26. Percent Change From Baseline in Lean Body Mass by BIA at Week 48

    Percent change from baseline in lean body mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

    Time frame: Baseline, Week 48

  27. Percent Change From Baseline in Lean Body Mass by BIA at Week 72

    Percent change from baseline in lean body mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

    Time frame: Baseline, Week 72

  28. Percentage of Participants With Body Mass Index (BMI) Categories at Baseline and Week 48

    BMI categories: i. Healthy weight: 18.5 kilograms (kg)/meter (m)² to 24.9 kg/m² ii. Overweight: 25 kg/m² to 29.9 kg/m² iii. Obesity class 1: 30 kg/m² to 34.9 kg/m² iv. Obesity class II: 35 kg/m² to 39.9 kg/m² v. Obesity class III: ≥ 40 kg/m2

    Time frame: Baseline, Week 48

  29. Percentage of Participants With Baseline Waist-to-Height Ratio (WtHR) Category of <0.5 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48

    WHtR ratio categories: \<0.5; 0.5-0.59; ≥0.6

    Time frame: Baseline up to 48 weeks

  30. Percentage of Participants With Baseline WtHR Category of 0.5-0.59 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48

    WHtR ratio categories: \<0.5; 0.5-0.59; ≥0.6

    Time frame: Baseline up to 48 weeks

  31. Percentage of Participants With Baseline WtHR Category ≥0.6 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48

    WHtR ratio categories: \<0.5; 0.5-0.59; ≥0.6

    Time frame: Baseline up to 48 weeks

  32. Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 48

    HbA1c is the glycosylated fraction of hemoglobin A. It is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

    Time frame: Baseline, 48 weeks

  33. Change From Baseline in Quality of Life Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score at Week 24

    The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores.

    Time frame: Baseline, Week 24

  34. Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score Week 24

    The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into (mental component score \[MCS\] and physical component score \[PCS\] to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.

    Time frame: Baseline, Week 24

  35. Change From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 48

    The SF-36v2 acute form assesses HRQoL on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10 items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores

    Time frame: Baseline, Week 48

  36. Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 48

    The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into MCS and PCS to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.

    Time frame: Baseline, Week 48

  37. Change From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 72

    The SF-36v2 acute form assesses HRQoL on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10 items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores

    Time frame: Baseline, Week 72

  38. Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 72

    The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into MCS and PCS to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.

    Time frame: Baseline, Week 72

  39. Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Score and Total Score at Week 24

    The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'

    Time frame: Baseline, Week 24

  40. Change From Baseline in IWQOL-Lite-CT Physical Function Score and Total Score at Week 48

    The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'

    Time frame: Baseline, Week 48

  41. Change From Baseline in IWQOL-Lite-CT Physical Function Score and Total Score at Week 72

    The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'

    Time frame: Baseline, Week 72

07

Results

Posted Jul 18, 2025

Participant flow

Participant flow — Overall Study
MilestonePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Started565657565756565657
Safety analysis population (received at least 1 dose of study drug)555657555656555655
Completed222527333928353735
Not completed343130231828211922
Withdrew: Adverse event8129468361
Withdrew: Lost to follow-up746459226
Withdrew: Non-compliance with study requirements323303214
Withdrew: Withdrawal by subject1310810768107
Withdrew: Physician decision011001400
Withdrew: Protocol violation001100102
Withdrew: Other322101102

Outcome measures

PrimaryChange From Baseline in Body Weight at Week 48

Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight at Week 48
kilogram (kg)Placebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Body Weight at Week 48-3.31 ± 1.39-5.99 ± 1.42-9.25 ± 1.33-9.76 ± 1.25-14.24 ± 1.17-12.73 ± 1.29-14.31 ± 1.34-13.86 ± 1.29-17.79 ± 1.29
Statistical analysis
  • Placebo/30 mg/kg Bimagrumab vs 30 mg/kg Bimagrumab + 2.4 mg Semaglutide · ANCOVA · p = <0.001 · Ls mean change difference: -14.5 · 95% CI -18.0 to -11.0
  • Placebo/30 mg/kg Bimagrumab vs 30 mg/kg Bimagrumab + 1.0 mg Semaglutide · ANCOVA · p = <0.001 · Ls mean change difference: -10.5 · 95% CI -14.0 to -7.09
  • Placebo/30 mg/kg Bimagrumab vs 10 mg/kg Bimagrumab + 2.4 mg Semaglutide · ANCOVA · p = <0.001 · Ls mean change difference: -11.0 · 95% CI -14.4 to -7.55
  • Placebo/30 mg/kg Bimagrumab vs 10 mg/kg Bimagrumab + 1.0 mg Semaglutide · ANCOVA · p = <.001 · Ls mean change difference: -9.41 · 95% CI -12.9 to -5.93
  • Placebo/30 mg/kg Bimagrumab vs Placebo + 2.4 mg Semaglutide · ANCOVA · p = <0.001 · Ls mean change difference: -10.9 · 95% CI -14.4 to -7.46
  • Placebo/30 mg/kg Bimagrumab vs Placebo + 1.0 mg Semaglutide · ANCOVA · p = <0.001 · Ls mean change difference: -6.45 · 95% CI -9.96 to -2.94
  • Placebo/30 mg/kg Bimagrumab vs 30 mg/kg Bimagrumab · ANCOVA · p = <0.001 · Ls mean change difference: -5.94 · 95% CI -9.47 to -2.41
  • Placebo/30 mg/kg Bimagrumab vs 10/30 mg/kg Bimagrumab · ANCOVA · p = 0.133 · Ls mean change difference: -2.68 · 95% CI -6.18 to 0.82
SecondaryChange From Baseline in Waist Circumference at Week 48

Waist circumference was measured in standing position with a non-stretchable measuring tape to the nearest 0.1 centimeter (cm). Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · centimeter (cm)
Change From Baseline in Waist Circumference at Week 48
centimeter (cm)Placebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Waist Circumference at Week 48-4.71 ± 1.27-7.88 ± 1.28-10.64 ± 1.16-10.57 ± 1.22-13.60 ± 1.11-14.63 ± 0.90-16.55 ± 1.00-15.84 ± 1.10-19.03 ± 1.09
SecondaryChange From Baseline in Waist Circumference at Week 72

Waist circumference was measured in standing position with a non-stretchable measuring tape to the nearest 0.1 cm. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · centimeter (cm)
Change From Baseline in Waist Circumference at Week 72
centimeter (cm)Placebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Waist Circumference at Week 72-7.89 ± 1.32-9.59 ± 1.51-13.04 ± 1.30-10.40 ± 1.41-14.67 ± 1.33-15.59 ± 1.07-18.10 ± 1.24-18.21 ± 1.30-21.26 ± 1.26
SecondaryChange From Baseline in Total Body Fat Mass in Kilograms (kg) at Week 48

Change from baseline in total body fat mass in kg was assessed by Dual energy X-ray absorptiometry (DXA). Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Kilogram (kg)
Change From Baseline in Total Body Fat Mass in Kilograms (kg) at Week 48
Kilogram (kg)Placebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Total Body Fat Mass in Kilograms (kg) at Week 48-2.41 ± 0.76-6.90 ± 0.88-11.86 ± 1.03-7.49 ± 0.96-11.06 ± 0.86-14.17 ± 0.84-15.93 ± 0.85-15.33 ± 0.94-19.30 ± 0.82
SecondaryChange From Baseline in Total Body Fat Mass in kg at Week 72

Change from baseline in total body fat mass in kg was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Kilogram (kg)
Change From Baseline in Total Body Fat Mass in kg at Week 72
Kilogram (kg)Placebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Total Body Fat Mass in kg at Week 72-7.33 ± 0.87-7.84 ± 1.17-13.24 ± 1.19-7.66 ± 1.08-12.47 ± 1.07-15.85 ± 1.10-17.52 ± 1.13-16.72 ± 1.19-21.24 ± 1.13
SecondaryPercent Change From Baseline for Fat Mass by DXA at Week 48

Percent change from baseline for fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Percent change
Percent Change From Baseline for Fat Mass by DXA at Week 48
Percent changePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Percent Change From Baseline for Fat Mass by DXA at Week 48-5.53 ± 1.59-15.65 ± 1.97-25.23 ± 2.20-18.36 ± 2.28-24.57 ± 1.57-30.60 ± 1.70-35.85 ± 1.91-34.42 ± 2.02-42.06 ± 1.81
SecondaryPercent Change From Baseline for Fat Mass by DXA at Week 72

Percent change from baseline for fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Percent change
Percent Change From Baseline for Fat Mass by DXA at Week 72
Percent changePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Percent Change From Baseline for Fat Mass by DXA at Week 72-16.60 ± 2.11-18.45 ± 2.65-28.35 ± 2.45-18.97 ± 2.55-27.37 ± 2.11-33.58 ± 2.12-39.46 ± 2.46-37.26 ± 2.48-45.42 ± 2.12
SecondaryChange From Baseline in Visceral Adipose Tissue (VAT), Subcutaneous Adipose Tissue (SAT) and Trunk Fat Mass by DXA at Week 48

Change from baseline in VAT, SAT and trunk fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · kg
Change From Baseline in Visceral Adipose Tissue (VAT), Subcutaneous Adipose Tissue (SAT) and Trunk Fat Mass by DXA at Week 48
kgPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
VAT-0.05 ± 0.06-0.36 ± 0.04-0.61 ± 0.06-0.30 ± 0.05-0.43 ± 0.05-0.64 ± 0.06-0.83 ± 0.07-0.75 ± 0.07-0.82 ± 0.06
SAT-0.13 ± 0.07-0.51 ± 0.10-0.87 ± 0.10-0.54 ± 0.07-0.80 ± 0.10-1.00 ± 0.07-1.15 ± 0.09-1.10 ± 0.10-1.37 ± 0.10
Trunk fat mass-1.24 ± 0.49-4.51 ± 0.53-7.65 ± 0.63-4.45 ± 0.61-6.31 ± 0.56-8.41 ± 0.48-9.97 ± 0.49-9.52 ± 0.63-11.52 ± 0.47
SecondaryChange From Baseline in VAT, SAT and Trunk Fat Mass by DXA at Week 72

Change from baseline in VAT, SAT and trunk fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Kilogram (kg)
Change From Baseline in VAT, SAT and Trunk Fat Mass by DXA at Week 72
Kilogram (kg)Placebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
VAT-0.27 ± 0.07-0.39 ± 0.06-0.65 ± 0.06-0.33 ± 0.05-0.52 ± 0.05-0.67 ± 0.06-0.93 ± 0.09-0.74 ± 0.07-0.86 ± 0.07
SAT-0.47 ± 0.09-0.60 ± 0.12-0.98 ± 0.11-0.52 ± 0.09-0.91 ± 0.12-1.09 ± 0.10-1.25 ± 0.11-1.21 ± 0.13-1.51 ± 0.12
Trunk Fat Mass-4.55 ± 0.52-5.24 ± 0.67-8.61 ± 0.68-4.65 ± 0.67-7.30 ± 0.67-9.32 ± 0.63-11.06 ± 0.68-10.20 ± 0.78-12.86 ± 0.66
SecondaryPercentage of Participants With Reduction in Waist Circumference Greater Than or Equal to (≥) 5 cm at Week 48

Waist circumference was measured in a standing position with a non-stretchable measuring tape to the nearest 0.1 cm. Only participants with non-missing baseline value were included in analysis.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Reduction in Waist Circumference Greater Than or Equal to (≥) 5 cm at Week 48
percentage of participantsPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Percentage of Participants With Reduction in Waist Circumference Greater Than or Equal to (≥) 5 cm at Week 4845.771.078.466.782.495.1100.090.797.7
SecondaryPercentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48

Body weight was measured in kgs to the nearest 0.1 kg. Only participants with non-missing baseline value were included in analysis.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48
percentage of participantsPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Reduction in ≥ 5%40.058.183.873.392.297.6100.097.797.7
Reduction in ≥ 10% Body Weight8.629.051.448.980.468.392.581.495.3
Reduction in ≥ 15% Body Weight5.716.132.435.647.141.555.060.579.1
SecondaryPercentage of Participants With Reduction in Fat Mass ≥ 5% ≥ 10% ≥ 15% by DXA at Week 48

Only participants with non-missing baseline value were included in analysis.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Reduction in Fat Mass ≥ 5% ≥ 10% ≥ 15% by DXA at Week 48
percentage of participantsPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
≥ 5% reduction in Fat Mass43.393.397.280.097.9100.0100.0100.0100.0
≥ 10% reduction in Fat Mass23.390.088.964.491.597.697.597.6100.0
≥ 15% reduction in Fat Mass10.053.375.053.385.192.997.590.5100.0
SecondaryPercentage of Participants Achieving Fat Mass ≥ 10% Reduction With <5% Decrease in Lean Mass by DXA at Week 48

Only participants with non-missing baseline value were included in analysis.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Fat Mass ≥ 10% Reduction With <5% Decrease in Lean Mass by DXA at Week 48
percentage of participantsPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Percentage of Participants Achieving Fat Mass ≥ 10% Reduction With <5% Decrease in Lean Mass by DXA at Week 4816.783.377.826.719.161.965.076.267.4
SecondaryPercentage of Participants Achieving >5 kg Weight Loss and Fat Loss Index (FLI) of >70%, >80%, and >90% by DXA at Week 48

Fat Lost Index = % change in fat mass/% change in lean mass + % change in fat mass. Only participants with non-missing baseline value were included in analysis.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving >5 kg Weight Loss and Fat Loss Index (FLI) of >70%, >80%, and >90% by DXA at Week 48
percentage of participantsPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
>5kg Weight Loss and Fat Loss Index >70 %14.5526.7940.3541.8250.0062.5065.4564.2972.73
>5kg Weight Loss and Fat Loss Index >80 %12.7323.2136.8416.3617.8657.1456.3653.5761.82
>5kg Weight Loss and Fat Loss Index >90 %3.6419.6435.0912.735.3642.8641.8246.4341.82
SecondaryChange From Baseline in Body Fat Mass by Bioelectrical Impedance Analysis (BIA) at Week 48

Change from baseline in body fat mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · kg
Change From Baseline in Body Fat Mass by Bioelectrical Impedance Analysis (BIA) at Week 48
kgPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Body Fat Mass by Bioelectrical Impedance Analysis (BIA) at Week 48-2.72 ± 0.77-6.45 ± 0.78-9.84 ± 0.81-7.54 ± 0.93-10.83 ± 0.75-12.85 ± 0.69-14.71 ± 0.87-14.16 ± 0.82-16.87 ± 0.72
SecondaryChange From Baseline in Body Fat Mass by BIA at Week 72

Change from baseline in body fat mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · kg
Change From Baseline in Body Fat Mass by BIA at Week 72
kgPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Body Fat Mass by BIA at Week 72-5.69 ± 0.87-7.20 ± 0.97-10.24 ± 1.00-6.49 ± 1.12-11.56 ± 0.95-13.94 ± 0.97-14.86 ± 0.92-14.95 ± 0.97-19.43 ± 0.97
SecondaryPercent Change From Baseline in Body Fat by BIA at Week 48

Percent change from baseline in Body fat was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Fat by BIA at Week 48
Percent changePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Percent Change From Baseline in Body Fat by BIA at Week 48-1.49 ± 0.38-3.82 ± 0.45-5.70 ± 0.46-3.80 ± 0.65-5.18 ± 0.43-7.03 ± 0.42-8.47 ± 0.68-8.39 ± 0.61-9.33 ± 0.50
SecondaryPercent Change From Baseline in Body Fat by BIA at Week 72

Percent change from baseline in Body fat was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Fat by BIA at Week 72
Percent changePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Percent Change From Baseline in Body Fat by BIA at Week 72-3.63 ± 0.45-4.36 ± 0.54-5.65 ± 0.57-3.06 ± 0.75-5.46 ± 0.56-7.43 ± 0.62-8.29 ± 0.66-8.71 ± 0.63-11.33 ± 0.84
SecondaryChange From Baseline in Lean Mass by DXA at Week 48

Change from baseline in lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · kg
Change From Baseline in Lean Mass by DXA at Week 48
kgPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Lean Mass by DXA at Week 48-0.33 ± 0.531.48 ± 0.511.19 ± 0.55-2.86 ± 0.45-4.43 ± 0.35-1.28 ± 0.42-1.12 ± 0.54-0.65 ± 0.66-1.43 ± 0.50
SecondaryChange From Baseline in Lean Mass by DXA at Week 72

Change from baseline in lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · kg
Change From Baseline in Lean Mass by DXA at Week 72
kgPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Lean Mass by DXA at Week 721.89 ± 0.722.26 ± 0.561.28 ± 0.58-2.78 ± 0.48-4.05 ± 0.45-1.04 ± 0.54-1.78 ± 0.52-0.79 ± 0.70-1.84 ± 0.57
SecondaryPercent Change From Baseline in Lean Body Mass by DXA at Week 48

Percent change from baseline in lean body mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Lean Body Mass by DXA at Week 48
Percent changePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Percent Change From Baseline in Lean Body Mass by DXA at Week 48-0.54 ± 0.792.81 ± 0.842.39 ± 0.93-5.23 ± 0.79-7.90 ± 0.60-2.21 ± 0.78-1.92 ± 0.85-1.00 ± 1.01-2.51 ± 0.87
SecondaryPercent Change From Baseline in Lean Body Mass by DXA at Week 72

Percent change from baseline in lean body mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Lean Body Mass by DXA at Week 72
Percent changePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Percent Change From Baseline in Lean Body Mass by DXA at Week 723.51 ± 1.144.17 ± 0.962.71 ± 0.96-5.09 ± 0.86-7.23 ± 0.79-1.96 ± 0.96-2.89 ± 0.81-1.38 ± 1.11-3.00 ± 1.00
SecondaryPercent Change From Baseline in Appendicular Lean Mass by DXA at Week 48

Percent change from baseline in appendicular lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Appendicular Lean Mass by DXA at Week 48
Percent changePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Percent Change From Baseline in Appendicular Lean Mass by DXA at Week 48-0.87 ± 0.823.07 ± 1.142.47 ± 0.96-5.68 ± 0.89-9.43 ± 0.77-2.31 ± 0.79-2.22 ± 0.91-1.74 ± 1.00-2.28 ± 0.99
SecondaryPercent Change From Baseline in Appendicular Lean Mass by DXA at Week 72

Percent change from baseline in appendicular lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Appendicular Lean Mass by DXA at Week 72
Percent changePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Percent Change From Baseline in Appendicular Lean Mass by DXA at Week 724.76 ± 1.474.98 ± 1.162.78 ± 1.15-6.24 ± 1.09-9.08 ± 0.87-2.30 ± 1.13-3.87 ± 0.86-2.29 ± 1.13-2.40 ± 1.29
SecondaryChange From Baseline in Lean Mass (kg) by BIA at Week 48

Change from baseline in lean mass (kg) was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · kg
Change From Baseline in Lean Mass (kg) by BIA at Week 48
kgPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Lean Mass (kg) by BIA at Week 48-0.57 ± 0.38-0.13 ± 0.55-1.68 ± 0.46-3.40 ± 0.69-4.40 ± 0.44-2.73 ± 0.37-3.15 ± 0.52-2.73 ± 0.55-4.62 ± 0.48
SecondaryChange From Baseline in Lean Mass (kg) by BIA at Week 72

Change from baseline in lean mass (kg) was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · kg
Change From Baseline in Lean Mass (kg) by BIA at Week 72
kgPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Lean Mass (kg) by BIA at Week 720.30 ± 0.49-0.54 ± 0.56-2.45 ± 0.62-4.34 ± 0.64-5.01 ± 0.45-3.32 ± 0.48-5.79 ± 1.11-3.95 ± 0.57-4.50 ± 0.82
SecondaryPercent Change From Baseline in Lean Body Mass by BIA at Week 48

Percent change from baseline in lean body mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Lean Body Mass by BIA at Week 48
Percent changePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Percent Change From Baseline in Lean Body Mass by BIA at Week 481.71 ± 0.523.62 ± 0.475.35 ± 0.474.02 ± 0.675.09 ± 0.406.83 ± 0.458.29 ± 0.697.23 ± 0.928.91 ± 0.50
SecondaryPercent Change From Baseline in Lean Body Mass by BIA at Week 72

Percent change from baseline in lean body mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Lean Body Mass by BIA at Week 72
Percent changePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Percent Change From Baseline in Lean Body Mass by BIA at Week 722.29 ± 1.554.05 ± 0.574.65 ± 0.682.80 ± 1.174.66 ± 0.896.52 ± 1.416.89 ± 1.376.79 ± 1.3410.64 ± 0.84
SecondaryPercentage of Participants With Body Mass Index (BMI) Categories at Baseline and Week 48

BMI categories: i. Healthy weight: 18.5 kilograms (kg)/meter (m)² to 24.9 kg/m² ii. Overweight: 25 kg/m² to 29.9 kg/m² iii. Obesity class 1: 30 kg/m² to 34.9 kg/m² iv. Obesity class II: 35 kg/m² to 39.9 kg/m² v. Obesity class III: ≥ 40 kg/m2

Time frame:
Baseline, Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Body Mass Index (BMI) Categories at Baseline and Week 48
percentage of participantsPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Healthy weight (Baseline)000000000
Overweight (Baseline)1.85.41.814.55.43.69.11.85.5
Obesity class I (Baseline)29.139.329.827.335.728.627.325.034.5
Obesity class II (Baseline)4030.438.627.332.130.429.15027.3
Obesity class III (Baseline)29.12529.830.926.837.534.523.232.7
Healthy weight (Week 48)002.717.83.92.410711.6
Overweight (Week 48)11.419.421.628.933.331.72525.637.2
Obesity class I (Week 48)37.132.343.217.851.031.737.553.527.9
Obesity class II (Week 48)31.435.521.617.87.826.822.511.614
Obesity class III (Week 48)2012.910.817.83.97.352.39.3
SecondaryPercentage of Participants With Baseline Waist-to-Height Ratio (WtHR) Category of <0.5 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48

WHtR ratio categories: \<0.5; 0.5-0.59; ≥0.6

Time frame:
Baseline up to 48 weeks

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Baseline WtHR Category of 0.5-0.59 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48

WHtR ratio categories: \<0.5; 0.5-0.59; ≥0.6

Time frame:
Baseline up to 48 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Baseline WtHR Category of 0.5-0.59 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48
percentage of participantsPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
WtHR Category: <0.500—50.000——25.0
WtHR Category: 0.5-0.5960.0100.0—50.066.7100.0——75.0
WtHR Category: ≥0.640.00—033.30——0
SecondaryPercentage of Participants With Baseline WtHR Category ≥0.6 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48

WHtR ratio categories: \<0.5; 0.5-0.59; ≥0.6

Time frame:
Baseline up to 48 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Baseline WtHR Category ≥0.6 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48
percentage of participantsPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
WtHR Category: <0.5005.42.62.107.72.315.4
WtHR Category: 0.5-0.5920.017.921.625.631.338.538.551.235.9
WtHR Category: ≥0.680.082.173.071.866.761.553.846.548.7
SecondaryChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 48

HbA1c is the glycosylated fraction of hemoglobin A. It is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.

Time frame:
Baseline, 48 weeks
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 48
percentage of HbA1cPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 48-0.01 ± 0.05-0.20 ± 0.04-0.17 ± 0.06-0.34 ± 0.03-0.39 ± 0.03-0.37 ± 0.03-0.56 ± 0.04-0.44 ± 0.03-0.48 ± 0.03
SecondaryChange From Baseline in Quality of Life Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score at Week 24

The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · t-score
Change From Baseline in Quality of Life Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score at Week 24
t-scorePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Quality of Life Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score at Week 246.91 ± 2.339.74 ± 1.4811.61 ± 1.6211.50 ± 1.5611.02 ± 1.9712.20 ± 1.8912.75 ± 1.9212.71 ± 1.9412.45 ± 1.93
SecondaryChange From Baseline in Quality of Life SF-36v2 Acute Form Total Score Week 24

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into (mental component score \[MCS\] and physical component score \[PCS\] to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score Week 24
score on a scalePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score Week 246.47 ± 2.114.69 ± 1.989.70 ± 1.6511.95 ± 1.5612.26 ± 1.4912.96 ± 2.0210.09 ± 2.1113.82 ± 1.6213.31 ± 1.45
SecondaryChange From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 48

The SF-36v2 acute form assesses HRQoL on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10 items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · t-score
Change From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 48
t-scorePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 4811.30 ± 1.8011.72 ± 2.5113.41 ± 1.6411.68 ± 2.4211.58 ± 2.1416.34 ± 1.5515.14 ± 1.8215.27 ± 1.9718.25 ± 2.19
SecondaryChange From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 48

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into MCS and PCS to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · score on a scale
Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 48
score on a scalePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 4810.02 ± 2.088.32 ± 2.0011.31 ± 1.7713.62 ± 1.7914.27 ± 1.6715.99 ± 1.9016.42 ± 1.9217.03 ± 1.6017.69 ± 1.90
SecondaryChange From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 72

The SF-36v2 acute form assesses HRQoL on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10 items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · t-score
Change From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 72
t-scorePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 727.35 ± 3.8113.70 ± 2.6515.90 ± 1.6214.06 ± 1.7513.52 ± 2.2817.36 ± 1.7714.41 ± 1.9717.04 ± 2.2020.91 ± 1.76
SecondaryChange From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 72

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into MCS and PCS to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · score on a scale
Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 72
score on a scalePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 728.03 ± 3.496.96 ± 3.0212.28 ± 1.9113.84 ± 2.1013.96 ± 2.0416.98 ± 1.9114.37 ± 2.1218.26 ± 1.7617.85 ± 1.59
SecondaryChange From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Score and Total Score at Week 24

The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'

Time frame:
Baseline, Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Score and Total Score at Week 24
score on a scalePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Physical Function Score7.973 ± 15.91913.289 ± 13.11513.974 ± 13.72616.667 ± 14.61617.447 ± 16.67714.659 ± 16.47412.105 ± 22.68018.690 ± 19.81821.667 ± 17.113
Total score8.142 ± 11.53810.789 ± 10.36315.513 ± 11.86817.639 ± 11.28519.468 ± 13.05518.977 ± 14.90114.671 ± 16.43417.113 ± 14.46322.917 ± 14.826
SecondaryChange From Baseline in IWQOL-Lite-CT Physical Function Score and Total Score at Week 48

The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · score on a scale
Change From Baseline in IWQOL-Lite-CT Physical Function Score and Total Score at Week 48
score on a scalePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Physical Function Score13.45 ± 2.3717.96 ± 2.3719.39 ± 2.0916.98 ± 2.0721.39 ± 2.1420.62 ± 2.6223.21 ± 2.9726.69 ± 2.3022.96 ± 2.00
Total Score13.44 ± 1.9915.62 ± 1.9218.52 ± 2.1519.16 ± 1.9823.43 ± 1.9924.33 ± 2.1122.91 ± 2.5024.42 ± 2.1826.47 ± 2.29
SecondaryChange From Baseline in IWQOL-Lite-CT Physical Function Score and Total Score at Week 72

The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · score on a scale
Change From Baseline in IWQOL-Lite-CT Physical Function Score and Total Score at Week 72
score on a scalePlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Physical Function Score12.08 ± 3.1319.05 ± 2.5819.34 ± 2.4522.05 ± 1.8025.07 ± 2.5019.85 ± 2.1019.30 ± 2.3728.31 ± 2.7929.85 ± 2.39
Total Score14.08 ± 2.6217.98 ± 2.6919.12 ± 2.2324.43 ± 1.9125.46 ± 2.0726.97 ± 2.4121.47 ± 2.4928.14 ± 2.7832.19 ± 2.21

Adverse events

Collected over Baseline up to Week 104. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/30 mg/kg Bimagrumab0/55 (0%)5/55 (9.1%)46/55 (83.6%)
10/30 mg/kg Bimagrumab0/56 (0%)9/56 (16.1%)54/56 (96.4%)
30 mg/kg Bimagrumab0/57 (0%)8/57 (14%)54/57 (94.7%)
Placebo + 1.0 mg Semaglutide0/55 (0%)4/55 (7.3%)52/55 (94.5%)
Placebo + 2.4 mg Semaglutide0/56 (0%)8/56 (14.3%)52/56 (92.9%)
10 mg/kg Bimagrumab + 1.0 mg Semaglutide0/56 (0%)7/56 (12.5%)53/56 (94.6%)
10 mg/kg Bimagrumab + 2.4 mg Semaglutide0/55 (0%)8/55 (14.5%)54/55 (98.2%)
30 mg/kg Bimagrumab + 1.0 mg Semaglutide0/56 (0%)6/56 (10.7%)54/56 (96.4%)
30 mg/kg Bimagrumab + 2.4 mg Semaglutide0/55 (0%)7/55 (12.7%)54/55 (98.2%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Post procedural haemorrhageInjury, poisoning and procedural complications0/550/560/570/550/560/560/550/562/55
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/550/562/571/550/560/560/550/561/55
Transient ischaemic attackNervous system disorders0/550/562/570/550/560/560/550/560/55
DiarrhoeaGastrointestinal disorders0/550/560/570/550/560/561/550/560/55
Mallory-weiss syndromeGastrointestinal disorders1/550/560/570/550/560/560/550/560/55
Obstructive pancreatitisGastrointestinal disorders1/550/560/570/550/560/560/550/560/55
PancreatitisGastrointestinal disorders0/551/560/571/550/560/560/550/560/55
Chest painGeneral disorders0/550/560/570/550/560/561/550/560/55
Cholecystitis acuteHepatobiliary disorders0/550/560/570/550/560/561/550/560/55
CholelithiasisHepatobiliary disorders0/551/560/570/551/561/560/551/561/55
Most frequent other events
Showing 10 of 670
Most frequent other events
EventPlacebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Muscle spasmsMusculoskeletal and connective tissue disorders22/5527/5641/578/556/5632/5636/5536/5635/55
NauseaGastrointestinal disorders9/5515/568/5725/5526/5623/5634/5520/5627/55
AcneSkin and subcutaneous tissue disorders20/5522/5628/577/556/5624/5625/5531/5629/55
DiarrhoeaGastrointestinal disorders10/5527/5629/5719/5521/5627/5629/5525/5627/55
Covid-19Infections and infestations11/5517/5616/5715/5518/5612/5612/5510/5612/55
Upper respiratory tract infectionInfections and infestations11/5513/5613/5714/5517/5611/5610/5516/5617/55
ConstipationGastrointestinal disorders3/552/563/5711/5516/568/5615/5517/569/55
FatigueGeneral disorders3/554/564/5713/5515/567/5611/558/5612/55
HeadacheNervous system disorders8/5511/567/5710/5513/5610/5612/5513/569/55
Abdominal painGastrointestinal disorders4/552/564/574/556/567/567/555/5610/55

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg SemaglutideTotal
Mean47.8 ± 14.644.4 ± 10.949.2 ± 12.250.3 ± 11.249.6 ± 11.844.8 ± 12.046.2 ± 11.747.7 ± 10.447.5 ± 12.747.5 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg SemaglutideTotal
Female323233323332323233291
Male242424242424242424216
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg SemaglutideTotal
Hispanic or Latino611342577853
Not Hispanic or Latino484453525450494748445
Unknown or Not Reported2110110219
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg SemaglutideTotal
American Indian or Alaska Native0011000013
Asian11103141315
Black63475756346
Native Hawaiian or Other Pacific Islander53211263124
Other64472523336
White384445404641394345381
Multiple0000000000
Unknown0100000012
Region of Enrollment
Region of Enrollment(Participants)Placebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg SemaglutideTotal
Australia12817919571414105
New Zealand242423262325302423222
United States202417211526191820180
Body Weight
Body Weight(kilogram (kg))Placebo/30 mg/kg Bimagrumab10/30 mg/kg Bimagrumab30 mg/kg BimagrumabPlacebo + 1.0 mg SemaglutidePlacebo + 2.4 mg Semaglutide10 mg/kg Bimagrumab + 1.0 mg Semaglutide10 mg/kg Bimagrumab + 2.4 mg Semaglutide30 mg/kg Bimagrumab + 1.0 mg Semaglutide30 mg/kg Bimagrumab + 2.4 mg SemaglutideTotal
Mean109.55 ± 19.33105.12 ± 19.50109.05 ± 17.56105.81 ± 20.02104.50 ± 14.82108.36 ± 18.92108.78 ± 18.41108.19 ± 14.34108.12 ± 18.48107.50 ± 17.97
08

Study locations

26 sites
  • Pinnacle Research Group, LLC
    Anniston, Alabama 36207, United States
  • Cullman Clinical Trials
    Cullman, Alabama 35055, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • Clinical Neuroscience Solutions Inc
    Jacksonville, Florida 32256, United States
  • Altus Research
    Lake Worth, Florida 33461, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
  • SPICA Clinical
    Columbia, South Carolina 29322, United States
  • Mt. Olympus Medical Research
    Sugar Land, Texas 77479, United States
  • Northern Beaches Clinical Research
    Brookvale, New South Wales 2100, Australia
  • Royal North Shore Hospital
    Saint Leonards, New South Wales 2065, Australia
  • University of The Sunshine Coast Morayfield
    Morayfield, Queensland 4506, Australia
  • University of the Sunshine Coast Clinical Trial Centre
    Sippy Downs, Queensland 04556, Australia
  • University of The Sunshine Coast South Brisbane
    South Brisbane, Queensland 4101, Australia
  • Gold Coast University Hospital
    Southport, Queensland 4215, Australia
  • Austin Health
    Heidelberg Heights, Victoria 3081, Australia
  • Emeritus Research
    Camberwell, 3124, Australia
  • Southern Clinical Trials Ltd
    Beckenham, Christchurch, Canterbury 8013, New Zealand
  • P3 Research
    Newtown, Wellington Region 6242, New Zealand
  • New Zealand Clinical Research Auckland
    Auckland, 1010, New Zealand
  • Optimal Clinical Trials
    Auckland, 1010, New Zealand
  • Middlemore Hospital
    Auckland, 2025, New Zealand
  • New Zealand Clinical Research Christchurch
    Christchurch, 8011, New Zealand
  • Lakeland Clinical Trials Waikato
    Hamilton, 3200, New Zealand
  • Southern Clinical Trials Tasman
    Nelson, 7011, New Zealand
09

References and documents

Publications

  • Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, Mindeholm L, Spruill S, Li X, Attie KM; BELIEVE trial investigators. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. 2026 Mar;32(3):869-882. doi: 10.1038/s41591-026-04204-0. Epub 2026 Mar 2. PubMed 41772149 ↗
  • Moon S, Choi JW, Park JH, Kim DS, Ahn Y, Kim Y, Kong SH, Oh CM. Association of Appendicular Skeletal Muscle Mass Index and Insulin Resistance With Mortality in Multi-Nationwide Cohorts. J Cachexia Sarcopenia Muscle. 2025 Apr;16(2):e13811. doi: 10.1002/jcsm.13811. PubMed 40230053 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in May 2024, 18 months.

Results were first posted in Jul 2025, 1 year 2 months after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 18 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2022
First posted
Nov 14, 2022
StartActual
Nov 16, 2022
Primary completionActual
May 16, 2024
CompletionActual
Jun 14, 2025
Results first posted
Jul 18, 2025
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05616013
Collaborators
Versanis Bio, Inc.
Responsible party
Sponsor
First posted
Nov 14, 2022
Start date
Nov 16, 2022
Primary completion
May 16, 2024
Completion
Jun 14, 2025
Results posted
Jul 18, 2025
Last update
Jul 8, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimagrumab

Start the discussion